Respiri (ASX:RSH) confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.
It said that it has already over two years' worth of inventory for its wheezo device in the US.
While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.
It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。